Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jan;69(1):172–176. doi: 10.1038/bjc.1994.29

Prognostic value of a novel circulating serum 90K antigen in breast cancer.

S Iacobelli 1, P Sismondi 1, M Giai 1, M D'Egidio 1, N Tinari 1, C Amatetti 1, P Di Stefano 1, C Natoli 1
PMCID: PMC1968766  PMID: 8286203

Abstract

Monoclonal antibody SP-2 to the tumour-associated antigen 90K was generated by immunisation with conditioned medium of human breast cancer cells. We investigated whether circulating levels of 90K can influence the prognosis of patients with breast cancer. Serum samples were obtained from 425 patients with histologically proven breast cancer with no clinical evidence of disease after surgery (NED) and in 310 patients with metastatic disease. Serum 90K was determined by a new immunoradiometric assay (IRMA). Antigen levels in NED patients were elevated in 18.5% of cases, mean levels being higher than in healthy controls (P = 0.001). Among 375 evaluable patients, the 75-month overall survival for 90K-negative (< or = 11 U ml-1) and 90K-positive (> 11 U ml-1) patients was 78% and 53% respectively (P = 0.004). The prognostic value of 90K appeared to be limited to patients with node-positive disease. Number of metastatic axillary lymph nodes and level of 90K antigen were the only independent variables for predicting overall survival. Patients with metastatic breast cancer had elevated 90K in 51.3% of cases. High 90K levels were significantly associated with the presence of metastases to liver, shorter disease-free interval and younger age. We conclude that an elevated 90K antigen level in serum is a predictor of poor prognosis in breast cancer.

Full text

PDF
172

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown J. P., Hewick R. M., Hellström I., Hellström K. E., Doolittle R. F., Dreyer W. J. Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature. 1982 Mar 11;296(5853):171–173. doi: 10.1038/296171a0. [DOI] [PubMed] [Google Scholar]
  2. Brown J. P., Nishiyama K., Hellström I., Hellström K. E. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J Immunol. 1981 Aug;127(2):539–546. [PubMed] [Google Scholar]
  3. Colomer R., Ruibal A., Genollá J., Rubio D., Del Campo J. M., Bodi R., Salvador L. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat. 1989 Mar;13(2):123–133. doi: 10.1007/BF01806524. [DOI] [PubMed] [Google Scholar]
  4. Dippold W. G., Lloyd K. O., Li L. T., Ikeda H., Oettgen H. F., Old L. J. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6114–6118. doi: 10.1073/pnas.77.10.6114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Iacobelli S., Arno E., Sismondi P., Natoli C., Gentiloni N., Scambia G., Giai M., Cortese P., Panici P. B., Mancuso S. Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Treat. 1988 Apr;11(1):19–30. doi: 10.1007/BF01807554. [DOI] [PubMed] [Google Scholar]
  6. Iacobelli S., Arnò E., D'Orazio A., Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986 Jun;46(6):3005–3010. [PubMed] [Google Scholar]
  7. Iacobelli S., Bucci I., D'Egidio M., Giuliani C., Natoli C., Tinari N., Rubistein M., Schlessinger J. Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett. 1993 Mar 15;319(1-2):59–65. doi: 10.1016/0014-5793(93)80037-u. [DOI] [PubMed] [Google Scholar]
  8. Kufe D. W., Nadler L., Sargent L., Shapiro H., Hand P., Austin F., Colcher D., Schlom J. Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res. 1983 Feb;43(2):851–857. [PubMed] [Google Scholar]
  9. Liao S. K., Kwong P. C., Khosravi M. J. Immunopurification, characterization, and nature of membrane association of human melanoma-associated oncofetal antigen gp87 defined by monoclonal antibody 140.240. J Cell Biochem. 1985;27(3):303–316. doi: 10.1002/jcb.240270311. [DOI] [PubMed] [Google Scholar]
  10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  11. Mattes M. J., Real F. X., Furukawa K., Old L. J., Lloyd K. O. Class 1 (unique) tumor antigens of human melanoma: partial purification and characterization of the FD antigen and analysis of a mouse polyclonal antiserum. Cancer Res. 1987 Dec 15;47(24 Pt 1):6614–6619. [PubMed] [Google Scholar]
  12. Natali P. G., Wilson B. S., Imai K., Bigotti A., Ferrone S. Tissue distribution, molecular profile, and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. Cancer Res. 1982 Feb;42(2):583–589. [PubMed] [Google Scholar]
  13. Natoli C., Garufi C., Tinari N., D'Egidio M., Lesti G., Gaspari L. A., Visini R., Iacobelli S. Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. Br J Cancer. 1993 Mar;67(3):564–567. doi: 10.1038/bjc.1993.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Scambia G., Panici P. B., Baiocchi G., Gallo A., Laurelli G., Iacobelli S., Mancuso S. Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer. A preliminary report. Cancer. 1991 Dec 15;68(12):2582–2585. doi: 10.1002/1097-0142(19911215)68:12<2582::aid-cncr2820681210>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  15. Schlom J., Greiner J., Hand P. H., Colcher D., Inghirami G., Weeks M., Pestka S., Fisher P. B., Noguchi P., Kufe D. Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer. Cancer. 1984 Dec 1;54(11 Suppl):2777–2794. doi: 10.1002/1097-0142(19841201)54:2+<2777::aid-cncr2820541426>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  16. Suter M., Butler J. E., Peterman J. H. The immunochemistry of sandwich ELISAs--III. The stoichiometry and efficacy of the protein-avidin-biotin capture (PABC) system. Mol Immunol. 1989 Mar;26(3):221–230. doi: 10.1016/0161-5890(89)90075-8. [DOI] [PubMed] [Google Scholar]
  17. Young D. A., Prout G. R., Jr, Lin C. W. Production and characterization of mouse monoclonal antibodies to human bladder tumor-associated antigens. Cancer Res. 1985 Sep;45(9):4439–4446. [PubMed] [Google Scholar]
  18. Zhang D. S., Lin C. W. Immunochemical and biochemical characterizations of two monoclonal antibody-reacting antigens associated with human bladder carcinoma. Cancer Res. 1989 Dec 1;49(23):6621–6628. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES